phosphodiesterase 5 inhibitor

phosphodiesterase 5 inhibitor

member of a family of phosphodiesterase inhibitors. Specifically, cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5, which breaks down cGMP and terminates its action. This is the site of action of sildenafil and similar drugs used in the treatment of erectile dysfunction.
See also: sildenafil.
Synonym(s): PDE5
Farlex Partner Medical Dictionary © Farlex 2012
References in periodicals archive ?
ALYQ is a phosphodiesterase 5 inhibitor indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability.
Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction.
Tadalafil tablets are a phosphodiesterase 5 inhibitor indicated for the treatment of erectile dysfunction, the signs and symptoms of benign prostatic hyperplasia, and both ED and the signs and symptoms of BPH.
Link et al., "Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice, " Molecular Immunology, vol.
Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model.
A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with a-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.
Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy.
Adcirca is a phosphodiesterase 5 inhibitor (PDE5i) indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability.
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with [alpha]-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Treatment of phosphodiesterase 5 inhibitors shows insufficient effectiveness in the treatment of post-prostatectomy ED and it is believed that the transplantation of stem cells cultivated on the surface of nanofibrous meshes can promote cavernous neuronal regeneration and repair erectile dysfunction.
Food and Drug Administration (FDA) has ordered labeling changes for erectile-dysfunction (ED) medications known as phosphodiesterase 5 inhibitors to reflect a potential risk of sudden hearing loss associated with using the drugs.

Full browser ?